When was Excalipoint founded?

Excalipoint was founded in 2025 and raised its 1st funding round 1 year after it was founded.

Where is Excalipoint located?

Excalipoint is headquartered in Shanghai, China.

Who is the current CEO of Excalipoint?

Lei Fang of Excalipoint. They have also founded 1 company.

How many employees does Excalipoint have?

As of Mar 31, 2026, the latest employee count at Excalipoint is 5.

Is Excalipoint a funded company?

Excalipoint is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Mar 18, 2026.

When was the latest funding round of Excalipoint?

Excalipoint's latest funding was a $***** Seed round on Mar 18, 2026, with participation from 11 investors.

Where does Excalipoint rank among its competitors?

Excalipoint ranks 166th amongst 1702 active competitors, of which 83 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Excalipoint, which secured $68.7M in Mar, 2026.

Who are the top competitors of Excalipoint?

Excalipoint's top competitors include AbbVie, Amgen and Gilead. Among them, Excalipoint secured the most recent funding round in March, 2026.

Excalipoint - 2026 Company Profile, Team, Funding & Competitors

Excalipoint is a seed company based in Shanghai (China), founded in 2025 by Jielun Zhu and Lei Fang. It operates as a Biotechnology company developing next-generation T-cell engager platforms for cancer and autoimmune diseases. Excalipoint has raised $68.7M in funding. The company has 1702 active competitors, including 83 funded and 177 that have exited. Its top competitors include companies like AbbVie, Amgen and Gilead.

Company Details

Biotechnology company developing next-generation T-cell engager platforms for cancer and autoimmune diseases. The company aims to overcome tumor challenges in immunology and oncology.

Key Metrics

Founded Year

2025

Location

Shanghai, China

Stage

Seed

Total Funding

$68.7M in 1 round

Latest Funding Round

Seed, Mar 18, 2026, $*****

Investors

Hony Capital & 10 more

Ranked

166^th among 1702 active competitors

Employee Count

5 as on Mar 31, 2026

Similar Companies

AbbVie & 1729 more

View Excalipoint's full profile

Excalipoint has raised a total funding of $68.7M over 1 round. Its latest funding round was a Seed round on Mar 18, 2026 for $*****. 11 investors participated in its latest round. Excalipoint has 11 institutional investors.

Here is the list of recent funding rounds of Excalipoint:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 18, 2026	3207298	Seed	9511359	4982602	9056319	2996994

Access funding benchmarks and valuations. Sign up today!

View details of Excalipoint's funding rounds and investors

The founders of Excalipoint are Jielun Zhu and Lei Fang. Lei Fang is the CEO of Excalipoint.

Here are the details of Excalipoint's key team members:

Jielun Zhu: Co-Founder & CFO & CBO of Excalipoint.
Lei Fang: Co-Founder & CEO & Chairman of Excalipoint.

View details of Excalipoint's Founder profiles and Board Members

Excalipoint's employee count trend

Excalipoint has 5 employees as of Mar 26. Here is Excalipoint's employee count trend over the years:

Uncover Excalipoint's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Excalipoint include AbbVie, Amgen and Gilead. Here is the list of Top 10 competitors of Excalipoint, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	AbbVie 2012, Chicago (United States), Public	Research-based biopharmaceutical company	$14.7B	Alcor Fund, Berkshire Hathaway & 8 others	81/100
2nd	Amgen 1980, Thousand Oaks (United States), Public	Developer of pharmaceutical products for treating multiple diseases	-	Digital Pharma Lab, Amgen Business Development ... & 11 others	81/100
3rd	Gilead 1987, Foster City (United States), Acquired	Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others	-	Menlo Ventures, Jindal ventures & 17 others	80/100
4th	Lilly 1876, Indianapolis (United States), Public	Developer of traditional pharmaceutical medicines	-	Alcor Fund, Digital Pharma Lab & 11 others	79/100
5th	Johnson & Johnson 1886, New Brunswick (United States), Public	Manufacturer and supplier of beauty care products, medical devices, and pharmaceutical products	-	Alcor Fund, 27th Street Capital & 16 others	76/100
6th	AstraZeneca 1999, Cambridge (United Kingdom), Public	Developer of pharmaceutical medicines for oncology and various chronic diseases	-	Digital Pharma Lab, Columbia Capital & 13 others	73/100
7th	Roivant Sciences 2014, New York City (United States), Public	Developer of therapeutics to treat neurology, oncology, rare, and endocrinology based diseases	$1.3B	SoftBank Vision Fund, NovaQuest Capital Management ... & 8 others	72/100
8th	Regeneron Pharmaceuticals 1988, Tarrytown (United States), Public	Developer of antibodies for the treatment of cancer, eye diseases, inflammatory diseases & others	-	Gershon Capital, Kaccelerator & 7 others	71/100
9th	Novartis 1996, Basel (Switzerland), Acquired	R&D focused on manufacturing of drugs for multiple therapeutic areas	-	Digital Pharma Lab, Atlas Venture & 9 others	71/100
10th	Roche 1896, Basel (Switzerland), Public	Developer of pharmaceuticals and diagnostics kits	-	Gilde Healthcare, Triodos Investment Management ... & 11 others	70/100
166th	Excalipoint 2025, Shanghai (China), Seed	Biotechnology company developing next-generation T-cell engager platforms for cancer and autoimmune diseases	$68.7M	Hony Capital, Centurium Capital & 9 others	37/100